>>9961751

It ischeaper than slavery.

Here is how Looking Glass works.

The enemy does not like to actually commit acts that are crimes in their system of law.

Lying is not a crime.

Stealing stuff that is not protected is not a crime.

But killing somebody is very bad.

Rape is almost as bad. Never rape, always get consent first.

Pay them for sex.

Frighten them into consenting.

Make promises if they consent

Threaten to harm their loved ones unless they consent.

And the best yet, warn them in advance and if they walk into your trap, they have already consented.

So Project Looking Glass hunts for the advance warnings like this attached document, figures out the plan, and takes COUNTERmeasures. This has to be done in secret because if they find out they will simply abandon the plan and do something different. You want them to believe that WE are walking into THEIR trap, but in reality, we have converted it into a trap for THEM.

Page 18 of the attached PDF

>>9962023

They're a bit late with that…

Vaxart Announces First Quarter 2020 Financial Results and Provides Corporate Update

https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-first-quarter-2020-financial-results-and

Vaxart, Inc. (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced financial results for the first quarter ended March 31, 2020 and provided a corporate update.

“In January we pivoted to COVID-19, and we are now on track to start a first Phase 1 study in the second half of this year with our oral tablet vaccine,” said Wouter Latour, MD, chief executive officer of Vaxart. “We are developing a state-of-the-art gene-based vaccine utilizing our proprietary vector platform, and the lead candidate vaccines performed well in preclinical testing, generating very high levels of antibodies.”

“For COVID-19, a key challenge will be to manufacture sufficient vaccine and efficiently vaccinate the millions at risk, and ultimately the entire population. Our vaccines are administered orally using a room temperature-stable tablet, an enormous logistical advantage over injectable vaccines in large vaccination campaigns. The bulk vaccine does not require sterile fill and finish, a significant bottleneck for injectable vaccines, but can be tableted very efficiently using high throughput industrial tableting equipment.”

Corporate Highlights:

In preclinical testing, the Company’s lead vaccine candidates generated robust anti-SARS CoV-2 antibodies in all tested animals after both the first and second dose, with a clear boosting effect after the second dose. Antibody responses in all vaccinated groups were statistically significant (p<0.002), with median ELISA IgG antibody titers above 10,000 compared to a median titer of 1 in the untreated controls, a larger than 10,000 fold increase.

The manufacturing collaboration with Emergent BioSolutions is progressing well and, provided Vaxart elects to proceed, Emergent is on schedule to produce bulk cGMP vaccine in time for initiation of a Phase 1 clinical study during the second half of 2020.

The Universal Influenza vaccine collaboration with Janssen remains on schedule to provide results by mid-2020.

The Company continues to pursue strategic, financial and public-private partnerships to advance its development candidates, including its coronavirus vaccine candidates, norovirus and seasonal influenza vaccine programs.

>>9962209

Vaxart Oral COVID-19 Vaccine Joins Trump’s “Warp Speed,” Ramps Up Manufacturing Capacity

https://www.genengnews.com/news/vaxart-oral-covid-19-vaccine-joins-trumps-warp-speed-ramps-up-manufacturing-capacity/

Vaxart’s oral COVID-19 vaccine candidate has joined the handful of experimental vaccines being studied as part of President Donald Trump’s commitment to delivering 300 million vaccine doses protecting against SARS-CoV-2 by January 2021—while the company gears up to manufacture as many as one billion doses a year.

The South San Francisco, CA, vaccine developer said Friday that its room temperature stable tablet vaccine had been selected for a non-human primate (NHP) challenge study organized and funded by Operation Warp Speed.

The study is designed to demonstrate the efficacy of Vaxart’s COVID-19 vaccine candidate, which is based on the company’s Vector-Adjuvant-Antigen Standardized Technology (VAAST™) Platform.

According to the company’s most recent investor presentation, Vaxart plans an IND submission for its COVID-19 vaccine “soon,” with a Phase I open-label, dose-ranging study set to enroll its first patient later this summer.

VAAST uses enteric-coated tablets designed to release in the small bowel the contents of the vaccine, which combines an adenovirus 5 (Ad5) vector, vaccine antigen, and a TLR3 adjuvant. VAAST vaccines are designed to activate the immune system of the gut, generating broad systemic and local responses—and are designed for a wide range of recombinant antigens.

Vaxart’s vaccine candidate has been upgraded to the second highest category, “Definitely Maybe,” in GEN’s updated “COVID-19 Drug & Vaccine Candidate Tracker,” which lists approximately 250 therapeutics under study.

>>9962140

Into The Blinding Light

I've been drinking Green Tea lately along with taking Zinc supplements. What about you?

Why was the word Pharmacy chosen in English instead of Apothecary like in other languages?

P = Pharmaceutical Industry?

pharmaceutical (adj.)

"pertaining to pharmacy or the art of preparing drugs," 1640s (pharmaceutic in the same sense is from 1540s), from Late Latin pharmaceuticus "of drugs," from Greek pharmakeutikos, from pharmakeus "preparer of drugs,poisoner" (see pharmacy). Pharmaceuticals "medicinal drugs" is attested by 1881. Related: Pharmaceutically.